The best predictive measure of the success of cancer treatment, universally for all forms of cancer, is how early the cancer is detected. At any size, tumors begin to rapidly shed DNA in blood circulation. Apostle is developing a technique to capture this circulating tumor DNA from a standard blood draw to help inform doctors if a patient is likely to have early stages of cancer, what form the cancer is in, and what treatment may be most successful against it. This will greatly benefit the entire population, as cancer is the leading cause of death globally.
We are positioning our company to be the pioneer in field of early cancer detection through blood-based liquid biopsy testing. Our ultimate vision is to develop an AI-enabled diagnostic system, using patent-pending nanoparticles reagents, that can use a standard blood draw to detect ultra-low levels of circulating tumor DNA, then use a best-in-class bioinformatics platform that plucks out hidden signatures to detect cancer at an earlier stage than is currently possible. This vision is feasible thanks to the 10x higher efficiency of our nanoparticle reagents as well as the AI-system that compares and learns from cancer big data.
In addition, our high-sensitivity technology can be used in a broad spectrum of clinical applications such as noninvasive prenatal testing (NIPT) and infectious diseases.
Apostle Inc is proud to have been awarded ISO 9001 certification for our
R&D, Manufacturing and Sales of Nucleic Acid Extraction and
This certificate demonstrates our commitment to providing a high-quality and consistent service to
our clients and our ongoing investment in technology, development, processes and procedures.
ISO 9001 is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. It is the most popular standard in the ISO 9000 series and the only standard in the series to which organizations can certify.
StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs
through experiential education and collective intelligence.
The Stanford-StartX Fund (SSF), co-founded by StartX, Stanford University, and Stanford Health Care is
available only to StartX companies with a Stanford-affiliated founder.
StartX alumni and trusted expert judges review and determine which teams are accepted. The acceptance rate has been between 8%-10%. Apostle is selected into the StartX Accelerator Program (Summer 2018 session), following one initial review, four interviews and due diligence.
Apostle Inc is selected into the Top 20 Life Science Startups to Watch in 2018 by BioSpace on January 2,
The NextGen Bio Class of 2018 is "a list of 20 up-and-coming life science companies in North America
that started up no earlier than 2015, a stellar group of companies that are already making an enormous
impact on the industry now and will into the future."
Companies in the field of genomic sciences selected in the past three years include:
Forbes China named Apostle Inc’s co-Founder and VP of Chemistry, Bo Zhang, PhD, as one of the most brilliant young entrepreneurs in its annual “30 Under 30 China” list in the category of healthcare and science.
Apostle Inc is selected into the Amazon Web Service (AWS) Activate Program.The AWS Activate Program is designed for startups in select accelerators, incubators, Seed/VC Funds, and other startup-enabling organizations. Some of the world’s hottest startups, including Airbnb, Slack, and Robinhood, have leveraged the power of AWS to quickly scale.
Apostle won the Second Place in the Final of North America Region, CACSC，(Create@AlibabaCloud Startup Contest). Over 300 startups from North America have competed in CACSC, and 13 entered the final.